Pipeline
Our Pipeline – Taking the “Scientific Innovation” to a bold new direction…
Given the global impact of infectious disease, we are developing a portfolio of drug candidates and vaccines which are cost effective and delivering to global population .
We create novel vaccines that could battle infectious diseases globally and help people live better lives.
RNA therapies is a quickly developing field. The efficacious and adaptable foundation around which these medicines are built has an almost limitless potential to meet unmet therapeutic needs. The treatment paradigm for many rare diseases is about to shift due to RNA therapeutics.
- Projects
- Discovery
- Pre - Clinical
- Phase 1
- Phase 2
- Commercial
- Projects
- Discovery
- Pre - Clinical
- Phase 1
- Phase 2
- Commercial
Global Infectious Disease Program
- LTX-101
- LTX-102
- LTX-103
Rare Disease Program
- LTX-201
- LTX-202
- LTX-203
- Projects
- Discovery
- Pre - Clinical
- Phase 1/2
- Phase 3
- License
- Commercial
- Projects
- Discovery
- Pre - Clinical
- Phase 1
- Phase 2
- Commercial
Rare Disease Programs (RNA Editing Platform)
- LTX-101
- Luminous
- $20B market
- LTX-102
- Luminous
- $1.4B market
- LTX-103
- Luminous
- $1B market
- LTX-104
- Luminous
- $1B market
Global Infectious Disease Programs (sa-RNA Platform)
- LTX-201
- Luminous
- $13B market
- LTX-202
- Luminous
- <$1B market
- LTX-203
- Luminous
- <$1B market
- LTX-204
- Luminous
- $9B market
